Get the Stockscreener App
38.63
0.69%
-0.27
Xenon Pharmaceuticals Inc stock is traded at $38.63, with a volume of 839.39K.
It is down -0.69% in the last 24 hours and down -1.80% over the past month.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
See More
Previous Close:
$38.90
Open:
$38.93
24h Volume:
839.39K
Relative Volume:
2.40
Market Cap:
$2.95B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-15.51
EPS:
-2.49
Net Cash Flow:
$-156.53M
1W Performance:
-3.55%
1M Performance:
-1.80%
6M Performance:
+4.15%
1Y Performance:
-5.78%
1-Day Range:
$38.00
$39.46
1-Week Range:
$37.52
$41.62
52-Week Range:
$35.53
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
38.63 | 2.95B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Franklin Resources Inc. - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin Sells 18,709 Shares - MarketBeat
Xenon Pharmaceuticals CFO sells shares worth $770,911 - Investing.com
Xenon Pharmaceuticals CFO sells shares worth $770,911 By Investing.com - Investing.com UK
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.1%Here's Why - MarketBeat
BNP Paribas Financial Markets Reduces Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals participates in a conference call with William Blair - Nasdaq
(XENE) Trading Advice - Stock Traders Daily
Citigroup Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - MSN
Lord Abbett & CO. LLC Trims Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook - Investing.com India
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook By Investing.com - Investing.com Australia
Xenon Pharmaceuticals’ (XENE) Buy Rating Reiterated at HC Wainwright - Defense World
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? - MSN
XENE Makes Notable Cross Below Critical Moving Average - Nasdaq
Xenon Pharmaceuticals (NASDAQ:XENE) Earns Buy Rating from HC Wainwright - MarketBeat
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - MarketBeat
Wellington Management Group LLP Buys 15,226 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Two Sigma Advisers LP Buys 64,800 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
(XENE) Technical Data - Stock Traders Daily
Point72 Asset Management L.P. Sells 98,732 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon's Azetukalner Shows Breakthrough Seizure Freedom Data: 33% of Patients Seizure-Free in Long-Term Study - StockTitan
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - The Manila Times
Xenon Pharmaceuticals named a Best Idea for 2025 at TD Cowen - MSN
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Janus Henderson Group PLC - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Erste Asset Management GmbH Acquires New Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
104,960 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Walleye Capital LLC - MarketBeat
Fmr LLC Has $272.35 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is Braidwell LP's 7th Largest Position - MarketBeat
Vestal Point Capital LP Has $32.48 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
Natixis Advisors LLC Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Loomis Sayles & Co. L P - MarketBeat
Xenon Pharmaceuticals Inc. to Showcase New Long-Term Azetukalner Data at AES 2024 - Marketscreener.com
Xenon Pharmaceuticals' SWOT analysis: stock poised for breakthrough in epilepsy - Investing.com
Xenon Pharmaceuticals Unveils New Data at AES 2024 - TipRanks
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 - The Manila Times
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Westfield Capital Management Co. LP - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 17,953 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Sells $200,922.28 in Stock - MarketBeat
Xenon Pharmaceuticals director sells $200,946 in stock - Investing.com India
Xenon Pharmaceuticals director sells $200,946 in stock By Investing.com - Investing.com Australia
First Turn Management LLC Sells 14,658 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Investors Eye Opportunities With Xenon Pharmaceuticals - Evrim Ağacı
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap DownHere's What Happened - MarketBeat
What is HC Wainwright's Estimate for XENE FY2024 Earnings? - MarketBeat
FY2024 EPS Estimates for XENE Reduced by Cantor Fitzgerald - MarketBeat
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xenon Pharmaceuticals Inc Stock (XENE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AULIN SHERRY | Chief Financial Officer |
Dec 18 '24 |
Sale |
41.21 |
18,709 |
770,912 |
0 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):